loading page

Biological and small molecule strategies in migraine therapy with relation to the CGRP family of peptides.
  • Lars Edvinsson (GUEST EDITOR),
  • Jacob Edvinsson,
  • Kristian Agmund Haanes
Lars Edvinsson (GUEST EDITOR)
Institute of Clinical Science in Lund, Lund University
Author Profile
Jacob Edvinsson
University of Copenhagen Faculty of Health and Medical Sciences
Author Profile
Kristian Agmund Haanes
Copenhagen University Hospital, Glostrup
Author Profile

Abstract

Migraine is one of the most common of neurological disorders with a global prevalence of up to 15%. One in five migraineurs have frequent episodic or chronic migraine requiring prophylactic treatment. In recent years, specific pharmaceutical treatments targeting calcitonin gene-related peptide (CGRP) signalling molecules have provided safe and effective treatments; monoclonal antibodies for prophylaxis and gepants for acute therapy. Albeit the beneficious impact of these new drugs, it is important to understand the molecular mechanisms involved to better understand migraine pathophysiology and improve the therapy. Here we describe current views on the role of the CGRP family of peptides CGRP, calcitonin (CT), adrenomedullin (AM), amylin (AMY) and their receptors in the trigeminovascular system (TGV). All these molecules are present within the TGV system but differ in expression and localization. It is likely that they have different roles, which can be utilized in providing additional drug targets.

Peer review status:UNDER REVIEW

27 Mar 2021Submitted to British Journal of Pharmacology
28 Mar 2021Submission Checks Completed
28 Mar 2021Assigned to Editor
03 Apr 2021Reviewer(s) Assigned
02 May 2021Review(s) Completed, Editorial Evaluation Pending
08 May 2021Editorial Decision: Revise Minor
28 May 20211st Revision Received
01 Jun 2021Submission Checks Completed
01 Jun 2021Assigned to Editor
02 Jun 2021Reviewer(s) Assigned